Abdullah Al Emran

1.0k total citations
32 papers, 719 citations indexed

About

Abdullah Al Emran is a scholar working on Molecular Biology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Abdullah Al Emran has authored 32 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 14 papers in Oncology and 7 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Abdullah Al Emran's work include Epigenetics and DNA Methylation (7 papers), Histone Deacetylase Inhibitors Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Abdullah Al Emran is often cited by papers focused on Epigenetics and DNA Methylation (7 papers), Histone Deacetylase Inhibitors Research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Abdullah Al Emran collaborates with scholars based in Australia, Bangladesh and United States. Abdullah Al Emran's co-authors include Peter Hersey, Jessamy Tiffen, Stuart Gallagher, Michael R. Eccles, Euan J. Rodger, Aniruddha Chatterjee, Heinz Hammerlindl, Helmut Schaider, Farzana Ahmed and Hsin‐Yi Tseng and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Research and Clinical Cancer Research.

In The Last Decade

Abdullah Al Emran

31 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Abdullah Al Emran Australia 16 464 210 174 98 51 32 719
Praveen Neeli United States 11 294 0.6× 127 0.6× 141 0.8× 77 0.8× 57 1.1× 23 541
Maricruz Anaya-Ruı́z Mexico 15 387 0.8× 164 0.8× 117 0.7× 175 1.8× 41 0.8× 45 716
Praveenkumar Shetty India 18 496 1.1× 122 0.6× 136 0.8× 181 1.8× 122 2.4× 58 847
Juan I. Barrasa Spain 10 404 0.9× 185 0.9× 95 0.5× 76 0.8× 34 0.7× 13 658
Elizabeth M. Park United States 8 401 0.9× 241 1.1× 102 0.6× 73 0.7× 62 1.2× 12 702
Moon Jong Kim South Korea 16 362 0.8× 153 0.7× 65 0.4× 86 0.9× 48 0.9× 30 680
Jamaal L. James United States 8 207 0.4× 179 0.9× 232 1.3× 73 0.7× 65 1.3× 9 563
Yusuke Nakamura Japan 13 414 0.9× 179 0.9× 48 0.3× 61 0.6× 62 1.2× 38 734
Chaozhi Jin China 13 338 0.7× 83 0.4× 169 1.0× 81 0.8× 20 0.4× 21 611

Countries citing papers authored by Abdullah Al Emran

Since Specialization
Citations

This map shows the geographic impact of Abdullah Al Emran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abdullah Al Emran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abdullah Al Emran more than expected).

Fields of papers citing papers by Abdullah Al Emran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abdullah Al Emran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abdullah Al Emran. The network helps show where Abdullah Al Emran may publish in the future.

Co-authorship network of co-authors of Abdullah Al Emran

This figure shows the co-authorship network connecting the top 25 collaborators of Abdullah Al Emran. A scholar is included among the top collaborators of Abdullah Al Emran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abdullah Al Emran. Abdullah Al Emran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Emran, Abdullah Al, Yutian Zhang, Yi Yang, et al.. (2025). Abstract 2115: SIM0680, a potent antibody-drug conjugate for the treatment of solid tumors expressing ENPP3. Cancer Research. 85(8_Supplement_1). 2115–2115.
2.
Tseng, Hsin‐Yi, Sara Alavi, Stuart Gallagher, et al.. (2024). BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment. Pigment Cell & Melanoma Research. 37(6). 744–751. 2 indexed citations
3.
Menon, Dinoop Ravindran, Heinz Hammerlindl, Grégory Gimenez, et al.. (2023). H3K4me3 remodeling induced acquired resistance through O-GlcNAc transferase. Drug Resistance Updates. 71. 100993–100993. 7 indexed citations
4.
Hossain, Md. Arju, et al.. (2022). Systems biology and in silico-based analysis of PCOS revealed the risk of metabolic disorders. Heliyon. 8(12). e12480–e12480. 5 indexed citations
5.
Emran, Abdullah Al, Hsin‐Yi Tseng, Dilini Gunatilake, et al.. (2021). A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology. 141(9). 2238–2249.e12. 10 indexed citations
6.
Ahmed, Farzana, Hsin‐Yi Tseng, Antonio Ahn, et al.. (2021). Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology. 142(5). 1444–1455.e10. 16 indexed citations
7.
Hersey, Peter, et al.. (2021). Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. Frontiers in Genetics. 12. 680633–680633. 16 indexed citations
8.
Emran, Abdullah Al, Stuart Gallagher, Jessamy Tiffen, & Peter Hersey. (2021). Sex bias of females in survival from cancer and infections. Is X the answer?. British Journal of Cancer. 124(7). 1184–1186. 4 indexed citations
9.
Tiffen, Jessamy, Stuart Gallagher, Fabian V. Filipp, et al.. (2020). EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. Journal of Investigative Dermatology. 140(12). 2442–2454.e5. 49 indexed citations
10.
Emran, Abdullah Al, Jérémie Nsengimana, Ulf Schmitz, et al.. (2020). Study of the Female Sex Survival Advantage in Melanoma—A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts. Cancers. 12(8). 2082–2082. 14 indexed citations
11.
Tseng, Hsin‐Yi, Abdullah Al Emran, Dilini Gunatilake, et al.. (2020). Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer. 147(8). 2176–2189. 20 indexed citations
12.
McGuire, Helen M., Abdullah Al Emran, Hsin‐Yi Tseng, et al.. (2020). Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology. 11. 372–372. 20 indexed citations
13.
Emran, Abdullah Al, Aniruddha Chatterjee, Euan J. Rodger, et al.. (2019). Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology. 40(4). 328–344. 158 indexed citations
14.
Emran, Abdullah Al, et al.. (2019). Emerging roles of H3K9me3, SETDB1 and SETDB2 in therapy-induced cellular reprogramming. Clinical Epigenetics. 11(1). 43–43. 62 indexed citations
15.
Hammerlindl, Heinz, Dinoop Ravindran Menon, Abdullah Al Emran, et al.. (2017). Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS -Mutant Cancers. Clinical Cancer Research. 24(5). 1090–1102. 15 indexed citations
16.
Waheed, Sajjad, et al.. (2016). Investigation of common disease regulatory network for metabolic disorders: A bioinformatics approach. SHILAP Revista de lepidopterología. 1 indexed citations
17.
Ahmed, Kawsar, et al.. (2016). Assessment of Menopausal Symptoms among Early and Late Menopausal Midlife Bangladeshi Women and Their Impact on the Quality of Life. Journal of Menopausal Medicine. 22(1). 39–39. 24 indexed citations
18.
Emran, Abdullah Al, et al.. (2015). TP53 Codon 72 Polymorphisms and Lung Cancer Risk in the Bangladeshi Population. Asian Pacific Journal of Cancer Prevention. 16(8). 3493–3498. 9 indexed citations
19.
Emran, Abdullah Al, et al.. (2014). Design of an epitope-based peptide vaccine against spike protein of human coronavirus: an in silico approach. Drug Design Development and Therapy. 8. 1139–1139. 75 indexed citations
20.
Saha, Sajal, et al.. (2012). Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects. Drug and Chemical Toxicology. 36(2). 149–154. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Praveen Neeli Breakdown of academic impact, for papers by Maricruz Anaya-Ruı́z Breakdown of academic impact, for papers by Praveenkumar Shetty Breakdown of academic impact, for papers by Juan I. Barrasa Breakdown of academic impact, for papers by Elizabeth M. Park Breakdown of academic impact, for papers by Moon Jong Kim Breakdown of academic impact, for papers by Jamaal L. James Breakdown of academic impact, for papers by Yusuke Nakamura Breakdown of academic impact, for papers by Chaozhi Jin
Rankless by CCL
2026